Lu-177-PSMA Radioligand Therapy for Prostate Cancer

Fendler, Wolfgang P.; Rahbar, Kambiz; Herrmann, Ken; Kratochwil, Clemens und Eiber, Matthias (2017): Lu-177-PSMA Radioligand Therapy for Prostate Cancer. In: Journal of Nuclear Medicine, Bd. 58, Nr. 8: S. 1196-1200

Abstract

Lu-177-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients withmetastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of Lu-177-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0161-5505
• Sprache: Englisch